title: [Anti-pneumococcal vaccination in 2014].
abstract: In 2007, due to the number of invasive pneumococcal infections and resistance to antibiotics, Belgium introduced juvenile anti-pneumococcal vaccination, recommending the 7-valent conjugate vaccine which provides better immune protection and memory than the 23-valent one for adults. In 2011, due to the increase in non-vaccine serotypes, the decision was taken to replace the 7-valent vaccine with a conjugate 13-valent one. Henceforth, essentially high-risk adults are given a 13-valent vaccine followed 8 weeks later by a 23-valent one, with a 23-valent booster every 5 years.
authors: M
authors: M
authors: Schetgen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001530:Belgium; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D013296:Streptococcus pneumoniae / Q000276:immunology; D018074:Vaccines, Conjugate / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate